Clinical Trials

AstraZeneca reports positive results of drug combination in late-stage ovarian cancer trial

AstraZeneca has announced positive high-level results from an interim analysis of the DUO-O phase 3 trial assessing a combination of Lynparza (olaparib) and Imfinzi (durvalumab) alongside chemotherapy and bevacizumab. This combination demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy plus bevacizumab.
The drug combination was assessed for newly diagnosed patients with advanced high-grade epithelial ovarian cancer without tumour BRCA mutations.
At this interim analysis, data showing overall survival and other secondary endpoints was incomplete – however, the PFS showed a statistically significant and clinically meaningful improvement, and data on this is expected to be presented at forthcoming medical meetings.
The safety and tolerability of the drug combinations was as expected from previous trials and remained consistent with known profiles of the individual drugs.
Philipp Harter, director of the Department of Gynaecology and Gynaecologic Oncology, Evangelische Kliniken Essen-Mitte, Germany, and principal investigator for the trial, commented: “DUO-O showcases the power of academia and industry collaboration in advancing new treatment combinations for patients with ovarian cancer. I’m grateful for the academic cooperative study groups and patients around the world that made this trial possible and look forward to sharing the results with the clinical community.”
Susan Galbraith, executive vice president of Oncology R&D at AstraZeneca, added: “While there has been significant progress for patients with advanced ovarian cancer, an unmet need still remains. These data from the DUO-O trial provide encouraging evidence for this Lynparza and Imfinzi combination in patients without tumour BRCA mutations and reinforce our continued commitment to finding new treatment approaches for these patients. It will be important to understand the key secondary endpoints as well as data for relevant subgroups.”